


Reduced CD34⁺ stem cells predicts CV outcome in T2DM

November 10 2016



(HealthDay)—Reduced baseline levels of circulating CD34⁺ stem cells

predict adverse cardiovascular outcomes for patients with type 2 diabetes, according to a study published online Nov. 4 in *Diabetes Care*.

Gian Paolo Fadini, M.D., Ph.D., from the University of Padova in Italy, and colleagues monitored a cohort of 187 [patients](#) with type 2 diabetes for a median of 6.1 years. Six stem/progenitor cell phenotypes were measured in peripheral blood at baseline, based on expression of CD34, CD133, and KDR.

The researchers found that the primary outcome of time to a first cardiovascular event plus hospitalization for cardiovascular causes occurred in 48 patients (4.5/100 patient-years). Significantly lower CD34⁺ and CD34⁺CD133⁺ cells were seen in patients with versus those without incident cardiovascular events. The rates of cardiovascular events were higher in patients with below median levels of CD34⁺ and CD34⁺CD133⁺. Reduced CD34⁺ and CD34⁺CD133⁺ cell count independently predicted future events in hazard regression analyses (hazard ratios, 2.21 and 2.98, respectively). C statistics, continuous net reclassification improvement, and/or integrated discrimination index were improved with addition of the CD34⁺ cell count to the reference model or the U.K. Prospective Diabetes Study risk engine.

"In patients with type 2 diabetes, a reduced baseline level of circulating CD34⁺ stem cells predicts adverse cardiovascular outcomes up to six years later and improves risk stratification," the authors write.

More information: [Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: Reduced CD34+ stem cells predicts CV outcome in T2DM (2016, November 10)

retrieved 3 May 2024 from

<https://medicalxpress.com/news/2016-11-cd34-stem-cells-cv-outcome.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.